Weight Loss

Pipeline Programs

Companies

Clinical Trials

2 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule

2100%

+ 23 programs with unclassified modality

Competitive Landscape

14 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

Viking TherapeuticsCA - San Diego

4 programs

VK2735Phase 31 trial

VK2735Phase 21 trial

VK2735Phase 11 trial

Active Trials

NCT05203237Completed92Est. Dec 2024

NCT06068946Completed176Est. Apr 2024

NCT07104500Active Not Recruiting4,500Est. Aug 2027

+1 more trials

Colorado TherapeuticsCO - Louisville

5 programs

DapagliflozinPhase 2Small Molecule1 trial

Dapagliflozin TabletPhase 21 trial

Beef groupN/A1 trial

International Weight Control RegistryN/A1 trial

Observation Group participantsN/A1 trial

Active Trials

NCT02627105Completed120Est. Nov 2016

NCT04907396Recruiting100,000Est. Dec 2025

NCT03257657Completed42Est. Feb 2018

+2 more trials

AstraZenecaCAMBRIDGE, United Kingdom

2 programs

DapagliflozinPhase 2Small Molecule

Dapagliflozin TabletPhase 2

BiomedAustralia - Sydney

1 program

Drug: Placebo daily and orallyPhase 21 trial

Active Trials

NCT06564753Completed126Est. Apr 2025

Angeles TherapeuticsCA - Los Angeles

2 programs

BrainWeighve AppN/A1 trial

high proteinN/A1 trial

Active Trials

NCT05530538Recruiting38Est. Jul 2027

NCT00523003Completed100Est. Mar 2006

Human BioSciencesWV - Martinsburg

2 programs

Commercial Weight Loss ProgramN/A1 trial

Dietary Protein IntakeN/A1 trial

Active Trials

NCT01785719Completed79Est. Dec 2023

NCT01292395Completed42Est. Nov 2011

Boston ScientificCA - Valencia

2 programs

OverStitch NXT Endoscopic Suture SystemN/A1 trial

Treatment groupN/A1 trial

Active Trials

NCT07276815Not Yet Recruiting136Est. Oct 2029

NCT07195708Not Yet Recruiting144Est. Oct 2028

ViiV HealthcareNC - Durham

1 program

Alli® 60 mgN/A

GSKLONDON, United Kingdom

1 program

Alli® 60 mgN/A1 trial

Active Trials

NCT02141230Withdrawn0Est. Feb 2016

Ildong PharmaceuticalKorea - Seoul

1 program

Belviq Tablet® Post Marketing Surveillance ProtocolN/A1 trial

Active Trials

NCT03741010Unknown3,000Est. Feb 2021

Purdue PharmaCT - Stamford

1 program

Energy RestrictionN/A1 trial

Active Trials

NCT00812162Completed48Est. Jul 2011

PhilipsNetherlands - Amsterdam

1 program

Healthdot attachmentN/A1 trial

Active Trials

NCT05368389Completed33Est. Jun 2023

Innovation PharmaceuticalsMA - Wakefield

1 program

Meal ReplacementN/A1 trial

Active Trials

NCT06614543Not Yet Recruiting40Est. Mar 2026

Young BioPharmaMA - Lowell

1 program

Transform BurnN/A1 trial

Active Trials

NCT06092840Completed36Est. Sep 2016

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

2028

2029

Viking TherapeuticsVK2735

BiomedDrug: Placebo daily and orally

Viking TherapeuticsVK2735

Colorado TherapeuticsDapagliflozin Tablet

Colorado TherapeuticsDapagliflozin

Viking TherapeuticsVK2735

Boston ScientificOverStitch NXT Endoscopic Suture System

Boston ScientificTreatment group

Innovation PharmaceuticalsMeal Replacement

Angeles TherapeuticsBrainWeighve App

PhilipsHealthdot attachment

Colorado TherapeuticsInternational Weight Control Registry

Colorado TherapeuticsObservation Group participants

Young BioPharmaTransform Burn

Showing 15 of 22 trials with date data

Clinical Trials (22)

Total enrollment: 109,923 patients across 22 trials

NCT07104500 Viking TherapeuticsVK2735

VK2735 for Weight Management Phase 3

Start: Jun 2025Est. completion: Aug 20274,500 patients

Phase 3Active Not Recruiting

NCT07104383 Viking TherapeuticsVK2735

VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

Start: Jun 2025Est. completion: Aug 20271,100 patients

Phase 3Active Not Recruiting

NCT06564753 BiomedDrug: Placebo daily and orally

Phase 2 Trials of NA-931 to Study Subjects Who Are Obese With at Least One Weight-related Comorbid Condition

Start: Jul 2024Est. completion: Apr 2025126 patients

Phase 2Completed

NCT06068946 Viking TherapeuticsVK2735

VK2735 for Weight Management Phase 2

Start: Aug 2023Est. completion: Apr 2024176 patients

Phase 2Completed

NCT03180489 Colorado TherapeuticsDapagliflozin Tablet

Does Dapagliflozin Provide Additional Health Benefits To Dietary Counseling For Weight Loss?

Start: May 2017Est. completion: Dec 201862 patients

Phase 2Completed

NCT02520518 Colorado TherapeuticsDapagliflozin

Does Dapagliflozin Promote Favorable Health Benefits That Are Independent Of Weight Loss?

Start: Aug 2015Est. completion: May 20179 patients

Phase 2Terminated

NCT05203237 Viking TherapeuticsVK2735

Phase 1 Study to Evaluate the Safety and Tolerability of VK2735

Start: Dec 2021Est. completion: Dec 202492 patients

Phase 1Completed

NCT07276815 Boston ScientificOverStitch NXT Endoscopic Suture System

OverStitch NXT Endoscopic Suture System

Start: Jul 2026Est. completion: Oct 2029136 patients

N/ANot Yet Recruiting

NCT07195708 Boston ScientificTreatment group

Orbera365 Intragastric Balloon System (Abbreviated as'Orbera365')

Start: May 2026Est. completion: Oct 2028144 patients

N/ANot Yet Recruiting

NCT06614543 Innovation PharmaceuticalsMeal Replacement

Feasibility Testing of Plant-Based Meal Replacement Products Made With Manitoba Crop Ingredients for Weight Loss and Diabetes Remission

Start: Sep 2025Est. completion: Mar 202640 patients

N/ANot Yet Recruiting

NCT05530538 Angeles TherapeuticsBrainWeighve App

BrainWeighve App Feasibility Study

Start: Nov 2023Est. completion: Jul 202738 patients

N/ARecruiting

NCT05368389 PhilipsHealthdot attachment

Observational Study of Wearable Health Monitoring Device

Start: Nov 2022Est. completion: Jun 202333 patients

N/ACompleted

NCT04907396 Colorado TherapeuticsInternational Weight Control Registry

International Weight Control Registry

Start: Dec 2020Est. completion: Dec 2025100,000 patients

N/ARecruiting

NCT03257657 Colorado TherapeuticsObservation Group participants

Helping Moms to be Healthy After Baby

Start: Jul 2017Est. completion: Feb 201842 patients

N/ACompleted

NCT06092840 Young BioPharmaTransform Burn

Effect of Transform Burn on Weight Loss

Start: Mar 2016Est. completion: Sep 201636 patients

N/ACompleted

NCT02141230 GSKAlli® 60 mg

Risk Management Plan (RMP) Survey for Purchasers of Alli® (60 mg Orlistat) in the European Union.

Start: Dec 2015Est. completion: Feb 20160

N/AWithdrawn

NCT02627105 Colorado TherapeuticsBeef group

The Beef WISE Study: Beef's Role in Weight Improvement, Satisfaction, and Energy

Start: Sep 2015Est. completion: Nov 2016120 patients

N/ACompleted

NCT03741010 Ildong PharmaceuticalBelviq Tablet® Post Marketing Surveillance Protocol

Belviq Tablet® Post Marketing Surveillance Protocol

Start: Feb 2015Est. completion: Feb 20213,000 patients

N/AUnknown

NCT01785719 Human BioSciencesCommercial Weight Loss Program

Evaluation of Ovarian Morphology and Function in Overweight Women During Weight Loss

Start: Jan 2013Est. completion: Dec 202379 patients

N/ACompleted

NCT01292395 Human BioSciencesDietary Protein Intake

Effects of Dietary Protein on Musculoskeletal Health During Calorie Deficiency

Start: Sep 2010Est. completion: Nov 201142 patients

N/ACompleted

NCT00812162 Purdue PharmaEnergy Restriction

Effects of Dietary Pork and Egg on Appetite, Meal-patterning, and Weight Loss in Men

Start: Jan 2007Est. completion: Jul 201148 patients

N/ACompleted

NCT00523003 Angeles Therapeuticshigh protein

A Controlled Trial of Protein Enrichment of Meal Replacements for Weight Reduction With Retention of Lean Body Mass

Start: May 2004Est. completion: Mar 2006100 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals

2 actively recruiting trials targeting 109,923 patients

17 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.